Jeffrey Cummings

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study
    Jeffrey L Cummings
    University of California, Los Angeles, Alzheimer s Disease Center, Los Angeles, California 90095 1769, USA
    Am J Geriatr Pharmacother 3:137-48. 2005
  2. ncbi Behavioral effects of current Alzheimer's disease treatments: a descriptive review
    Jeffrey L Cummings
    UCLA Alzheimer Disease Center, UCLA, Los Angeles, CA, USA
    Alzheimers Dement 4:49-60. 2008
  3. ncbi A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia
    Jeffrey Cummings
    UCLA Alzheimer s Center, 10911 Weyburn Avenue, Suite 200, Los Angeles, CA 90095 7226, USA
    Expert Rev Neurother 7:1457-63. 2007
  4. ncbi Disease-modifying therapies for Alzheimer disease: challenges to early intervention
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurology 69:1622-34. 2007
  5. ncbi Pharmacokinetic rationale for the rivastigmine patch
    Jeffrey Cummings
    UCLA Alzheimer s Center, Los Angeles, CA 90095 7226, USA
    Neurology 69:S10-3. 2007
  6. ncbi Clinical evaluation as a biomarker for Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, Alzheimer s Disease Research Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    J Alzheimers Dis 8:327-37. 2005
  7. ncbi Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Am J Geriatr Psychiatry 14:605-12. 2006
  8. ncbi ADCS Prevention Instrument Project: behavioral measures in primary prevention trials
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:S147-51. 2006
  9. ncbi Fluctuations in cognitive function in dementia with Lewy bodies
    Jeffrey L Cummings
    David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Lancet Neurol 3:266. 2004
  10. ncbi Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Neurology 67:57-63. 2006

Research Grants

  1. IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE
    Jeffrey Cummings; Fiscal Year: 2002

Detail Information

Publications93

  1. ncbi Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study
    Jeffrey L Cummings
    University of California, Los Angeles, Alzheimer s Disease Center, Los Angeles, California 90095 1769, USA
    Am J Geriatr Pharmacother 3:137-48. 2005
    ....
  2. ncbi Behavioral effects of current Alzheimer's disease treatments: a descriptive review
    Jeffrey L Cummings
    UCLA Alzheimer Disease Center, UCLA, Los Angeles, CA, USA
    Alzheimers Dement 4:49-60. 2008
    ....
  3. ncbi A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia
    Jeffrey Cummings
    UCLA Alzheimer s Center, 10911 Weyburn Avenue, Suite 200, Los Angeles, CA 90095 7226, USA
    Expert Rev Neurother 7:1457-63. 2007
    ..Treatment differences on the Neuropsychiatric Inventory and Ten Point Clock-drawing Test did not reach statistical significance in this study. The patch may be the optimal way to treat dementia patients with rivastigmine...
  4. ncbi Disease-modifying therapies for Alzheimer disease: challenges to early intervention
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurology 69:1622-34. 2007
    ..The neurologic health of the growing aging population demands disease-modifying therapies and the development of methods to identify and test promising candidate agents...
  5. ncbi Pharmacokinetic rationale for the rivastigmine patch
    Jeffrey Cummings
    UCLA Alzheimer s Center, Los Angeles, CA 90095 7226, USA
    Neurology 69:S10-3. 2007
    ..The potential of a patch to improve the tolerability of rivastigmine (e.g., nausea and vomiting) while permitting similar exposure to the highest doses of capsules may, in turn, lead to improved efficacy and compliance...
  6. ncbi Clinical evaluation as a biomarker for Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, Alzheimer s Disease Research Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    J Alzheimers Dis 8:327-37. 2005
    ..Biomarkers must closely reflect clinical outcomes to be useful as evaluations of disease progression or as outcomes in clinical trials...
  7. ncbi Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Am J Geriatr Psychiatry 14:605-12. 2006
    ..The authors report the effects of donepezil on behavioral disturbances in patients with relatively severe psychopathology at baseline...
  8. ncbi ADCS Prevention Instrument Project: behavioral measures in primary prevention trials
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:S147-51. 2006
    ..Experimental behavioral measures were included in the protocol to examine this hypothesis...
  9. ncbi Fluctuations in cognitive function in dementia with Lewy bodies
    Jeffrey L Cummings
    David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Lancet Neurol 3:266. 2004
  10. ncbi Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Neurology 67:57-63. 2006
    ..To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)...
  11. ncbi Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1769, USA
    N Engl J Med 351:56-67. 2004
  12. ncbi Optimizing phase II of drug development for disease-modifying compounds
    Jeffrey L Cummings
    Department of Neurology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Alzheimers Dement 4:S15-20. 2008
    ..in a successful drug development program; all have some promise for reforming phase II and answering the central question of "how much information is sufficient to proceed to phase III without excessive risk for failure?"..
  13. ncbi Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations
    Jeffrey Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Los Angeles, CA 90095 7226, USA
    J Alzheimers Dis 20:301-11. 2010
    ..3 points (p< 0.05). Interaction testing suggested that differences in treatment effects were significant between hallucinators and non-hallucinators. Hallucinations predicted greater treatment responses to oral rivastigmine...
  14. ncbi Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies
    Jeffrey L Cummings
    Department of Neurology, 710 Westwood Plaza, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    Nat Rev Drug Discov 5:64-74. 2006
    ....
  15. ncbi Biomarkers in Alzheimer's disease drug development
    Jeffrey L Cummings
    Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic Neurological Institute, Las Vegas, NV, USA
    Alzheimers Dement 7:e13-44. 2011
    ..Fit-for-purpose biomarkers are increasingly available to guide AD drug development decisions...
  16. ncbi Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis
    Jeffrey Cummings
    Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
    J Alzheimers Dis 21:843-51. 2010
    ..The treatment effect size and correlation between improvements in SIB scores and functional and global outcome measures suggest the drug-placebo differences are clinically meaningful...
  17. ncbi Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 29:406-12. 2010
    ..This was a hypothesis-forming study, designed to provide a basis for possible future research...
  18. ncbi Integrating ADNI results into Alzheimer's disease drug development programs
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, United States
    Neurobiol Aging 31:1481-92. 2010
    ....
  19. ncbi Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
    Clin Drug Investig 30:41-9. 2010
    ..The aim of the component of the trial reported here was to evaluate the skin tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate AD...
  20. ncbi Alzheimer's disease: from molecular biology to neuropsychiatry
    Jeffrey L Cummings
    Department of Neurology and Psychiatry, Reed Neurological Research Center, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Semin Clin Neuropsychiatry 8:31-6. 2003
    ..The steps of the amyloid cascade present multiple targets for drug development and identification of effective disease-modifying anti-Alzheimer's disease treatments...
  21. ncbi Defining and labeling disease-modifying treatments for Alzheimer's disease
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Alzheimers Dement 5:406-18. 2009
    ..Prevention claims will depend heavily on biomarker outcomes...
  22. ncbi Controversies in Alzheimer's disease drug development
    Jeffrey L Cummings
    Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Int Rev Psychiatry 20:389-95. 2008
    ..The questions surrounding these issues must be resolved as disease-modifying therapies for AD are advanced. These controversies are framed and potential directions towards resolution described...
  23. ncbi Dementia with lewy bodies: molecular pathogenesis and implications for classification
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Geriatr Psychiatry Neurol 17:112-9. 2004
    ..Classification systems based on symptom complexes related to the presence of protein misfolding will assist therapeutic decisions...
  24. ncbi Predicting cognitive decline in Alzheimer's disease: an integrated analysis
    Oscar L Lopez
    Department of Neurology, Alzheimer s Disease Research Center, University of Pittsburgh, Pittsburgh, PA, USA
    Alzheimers Dement 6:431-9. 2010
    ..Numerous patient- and disease-related factors increase the risk of rapid cognitive decline in patients with Alzheimer's disease (AD). The ability of pharmacological treatment to attenuate this risk remains undefined...
  25. ncbi ADCS Prevention Instrument Project: overview and initial results
    Steven H Ferris
    Alzheimer s Disease Center, New York University School of Medicine, New York, NY 10016, USA
    Alzheimer Dis Assoc Disord 20:S109-23. 2006
    ..Initial results for the experimental instruments and for the book club are reported in separate accompanying articles...
  26. ncbi Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias
    Verna R Porter
    Department of Neurology, University of California, Los Angeles, School of Medicine, USA
    J Neuropsychiatry Clin Neurosci 15:180-6. 2003
    ..These data suggest that anxiety is common among patients with diverse forms of dementia. In AD, anxiety is most common in those with more severe cognitive deterioration and an earlier age at onset...
  27. ncbi ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials
    David P Salmon
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093 0948, USA
    Alzheimer Dis Assoc Disord 20:S139-46. 2006
    ....
  28. ncbi Executive dysfunction in Alzheimer disease
    Margaret M Swanberg
    Department of Neurology, David Geffen School of Medicine at UCLA, 90095-1769, USA
    Arch Neurol 61:556-60. 2004
    ..CONCLUSION: These findings support the assessment of executive function in persons with AD and the importance of frontal lobe dysfunction in AD...
  29. ncbi Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms
    Tzung J Hwang
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095-1769, USA
    Alzheimer Dis Assoc Disord 18:17-21. 2004
    ..Psychotic symptoms are significantly more common in the early stage of AD than in MCI. These results are derived from a limited clinical sample and require confirmation in longitudinal community-based investigations...
  30. ncbi Dementia with parkinsonism: what is the diagnosis?
    Mei S Chong
    Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 1:41-4. 2004
    ..The 72-year-old patient whose case is reviewed here had abnormalities in all three domains...
  31. ncbi Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials
    Charles Bernick
    Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, Nevada 89106, USA
    Arch Neurol 69:901-5. 2012
    ..Factors that affect the rate of progression of Alzheimer disease (AD) need to be considered in the clinical trial designs of potential disease-modifying therapies...
  32. ncbi Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies
    Jeffrey L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 13:67-73. 2002
    ..CONCLUSIONS: This preliminary analysis suggests that olanzapine (5 or 10 mg) reduces psychosis in patients with DLB without worsening parkinsonism...
  33. ncbi Neuropathologic correlates of activities of daily living in Alzheimer disease
    Gad A Marshall
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1769, USA
    Alzheimer Dis Assoc Disord 20:56-9. 2006
    ..Deteriorating activities of daily living in Alzheimer Disease subjects correlate with greater overall pathologic burden and possibly selectively with involvement of the medial temporal, occipital, and orbital frontal regions...
  34. ncbi Early-onset Alzheimer's disease is associated with greater pathologic burden
    Gad A Marshall
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Geriatr Psychiatry Neurol 20:29-33. 2007
    ..This suggests that late-onset AD patients have less cognitive reserve than early-onset patients and require fewer pathologic changes to exhibit cognitive deterioration...
  35. ncbi Apolipoprotein epsilon4 status is associated with behavioral symptoms in nursing home residents with dementia
    Diana Lynn Woods
    School of Nursing, University of California, Los Angeles 90095 6919, USA
    Int Psychogeriatr 21:722-8. 2009
    ..The aim of this study was to examine the association between APOE genotype and BSD in NH residents using direct observation...
  36. ncbi Guidelines for managing Alzheimer's disease: part I. Assessment
    Jeffrey L Cummings
    University of California, Los Angeles, School of Medicine, USA
    Am Fam Physician 65:2263-72. 2002
    ..Suggestions for easily administered and scored assessment tools are provided, and practical tips are given for supporting primary caregivers, thereby increasing efficiency and quality of care for patients with Alzheimer's disease...
  37. ncbi Treatment of Alzheimer's disease: current and future therapeutic approaches
    Jeffrey L Cummings
    Department of Neurology, University of California, The David Geffen School of Medicine, Los Angeles, CA, USA
    Rev Neurol Dis 1:60-9. 2004
    ..Improved methodologies for clinical trial design and analysis and the development of biological markers may hasten the identification of effective treatments for AD...
  38. ncbi Positron emission tomography metabolic correlates of apathy in Alzheimer disease
    Gad A Marshall
    Department of Neurology, University of California, Los Angeles, CA, USA
    Arch Neurol 64:1015-20. 2007
    ....
  39. ncbi Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease
    Jeffrey Cummings
    Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV 89106, USA
    Dement Geriatr Cogn Disord 33:341-53. 2012
    ..5 mg/24 h (10 cm(2)) rivastigmine patch, benefit from a dose increase in a double-blind (DB) comparative trial of two patch doses...
  40. ncbi Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    Am J Geriatr Psychiatry 16:469-77. 2008
    ....
  41. ncbi A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Dement Geriatr Cogn Disord 25:301-8. 2008
    ..The aim of this review was to survey the recent literature on the pathology of PDD and compare the pathology of PDD to that of Alzheimer's disease (AD)...
  42. ncbi The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson's disease in Mexico
    John M Ringman
    Department of Neurology, UC Irvine School of Medicine, Irvine, California, USA
    Neuropsychiatry Neuropsychol Behav Neurol 15:99-105. 2002
    ..To study the incidence of behavioral abnormalities in patients with Parkinson's disease (PD) and extend them to a Mexican population...
  43. ncbi Association of GSK3B with Alzheimer disease and frontotemporal dementia
    Barbara A J Schaffer
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, 2506 Gonda, 695 Charles E Young Dr S, Los Angeles, CA 90095 1761, USA
    Arch Neurol 65:1368-74. 2008
    ..As a known tau kinase, GSK3B is a promising candidate gene in the remaining cases of FTD and in AD, for which tau mutations have not been found...
  44. ncbi Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease
    Jeffrey L Cummings
    UCLA Alzheimer s Disease Research Center, University of California, Los Angeles, CA, USA
    CNS Spectr 13:1-20; quiz 22. 2008
    ..Debra Cherry, PhD, discusses the advocacy needs of Alzheimer's disease patients and their caregivers. In addition, Patricia Utermohlen, MA, provides a testimonial of the impact of Alzheimer's disease on an accomplished artist...
  45. ncbi Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies
    Jeffrey L Cummings
    Departmentsof Neurology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 4:57-62. 2007
    ..Therapeutic regimens for the treatment of AD will include both disease-modifying and symptomatic agents...
  46. ncbi Guidelines for managing Alzheimer's disease: Part II. Treatment
    Jeffrey L Cummings
    University of California, Los Angeles, School of Medicine, USA
    Am Fam Physician 65:2525-34. 2002
    ..Throughout the course of the disease, routine use of community resources allows care to be provided by a network of professionals, many of whom will be specialists in Alzheimer's disease...
  47. ncbi Functional ability in executive variant Alzheimer's disease and typical Alzheimer's disease
    Carla Back-Madruga
    University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
    Clin Neuropsychol 16:331-40. 2002
    ....
  48. ncbi Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, USA
    Dement Geriatr Cogn Disord 25:115-26. 2008
    ..MCI is an important risk state for dementia. Neuropsychiatric symptoms may be present in MCI...
  49. ncbi Regression to the mean: implications for clinical trials of psychotropic agents in dementia
    Jeffrey L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Curr Alzheimer Res 1:323-8. 2004
    ..Research design adjustments such as collection of both screening and baseline measures to determine eligibility may limit the effects of regression to the mean on trial outcomes and reduce this challenge to clinical trials...
  50. ncbi Speech and language in progressive nonfluent aphasia compared with early Alzheimer's disease
    Mario F Mendez
    Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, USA
    Neurology 61:1108-13. 2003
    ..The differentiation of PA from early Alzheimer's disease (AD) is important, given the presence of early language changes in AD...
  51. ncbi Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, 10911 Weyburn Avenue, Los Angeles, CA 90095, USA
    Mol Imaging Biol 12:218-24. 2010
    ..The aim of this study was to investigate the longitudinal positron emission tomography (PET) metabolic changes in the elderly...
  52. ncbi Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Associate Clinical Professor, UCLA Department of Neurology, 10911 Weyburn Ave, 200, Los Angeles, CA 90095 7226, USA
    Curr Alzheimer Res 6:341-6. 2009
    ..The study of FAD provides an opportunity to test various criteria for early AD and these observations should be taken into consideration in future iterations of such diagnostic criteria...
  53. ncbi Alzheimer disease
    Jeffrey L Cummings
    Department of Neurology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    JAMA 287:2335-8. 2002
  54. ncbi Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairment
    Edmond Teng
    Neurobehavior Unit, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    Dement Geriatr Cogn Disord 30:189-97. 2010
    ..We explored the relationship between these factors by comparing instrumental activities of daily living (IADLs) among cognitive subtypes of MCI and examining associations between IADL and neuropsychological indices...
  55. ncbi 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
    Neurobiol Aging 31:1284-303. 2010
    ..p-tau(181) showed stronger correlation in ApoE4 carriers, while t-tau showed stronger correlation in ApoE4 noncarriers. Of the 3 PIB measures the precuneal SUVR showed strongest associations with hippocampal atrophy...
  56. ncbi Subcortical hyperintensities in Alzheimer's disease: associated clinical and metabolic findings
    David L Sultzer
    Departments of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, USA
    J Neuropsychiatry Clin Neurosci 14:262-9. 2002
    ..These preliminary findings indicate that subcortical MRI hyperintensities may play a role in the pathophysiology and clinical expression of Alzheimer's disease...
  57. ncbi Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer's disease
    Freddy Ortiz
    The Neuropsychiatry Research Memory Clinic, Olive View UCLA Medical Center, Sylmar, CA 91342, USA
    Am J Alzheimers Dis Other Demen 21:263-73. 2006
    ..These findings have implications for differential sociocultural presentations of Alzheimer's disease among ethnic/racial groups...
  58. ncbi 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Hum Brain Mapp 31:786-97. 2010
    ..Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses...
  59. ncbi Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative
    Jeffrey L Cummings
    Department of Neurology, The Mary S Easton Center for Alzheimer s Disease Research at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Alzheimers Dis 19:375-88. 2010
    ..The Center supports excellent senior 3 investigators and serves as an incubator for new scientists, agents, models, technologies and concepts that will significantly influence the future of AD treatment and AD research...
  60. ncbi Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Neuroimage 51:488-99. 2010
    ..After controlling for baseline hippocampal atrophy, memory performance showed regionally specific associations with hippocampal radial distance in predominantly CA1 but also in subicular distribution...
  61. ncbi Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, 10911 Westwood Blvd, Second Floor, Los Angeles, CA 90095, USA
    Arch Neurol 64:1489-95. 2007
    ..Most patients with MCI harbor the pathologic changes of AD and demonstrate transition to dementia at a rate of 10% to 15% per year. Patients with AD and MCI experience progressive brain atrophy...
  62. ncbi Behavioral and neuropsychiatric outcomes in Alzheimer's disease
    Jeffrey L Cummings
    Alzheimer s Disease Research Center, Department of Neurology, University of California Los Angeles, 710 Westwood Plaza Rm 2 238, Los Angeles, CA 90095, USA
    CNS Spectr 10:22-5. 2005
    ....
  63. ncbi Relational integration and executive function in Alzheimer's disease
    James A Waltz
    Departjment of Psychology, University of California, Los Angeles, CA 90095-1563, USA
    Neuropsychology 18:296-305. 2004
    ....
  64. ncbi 3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Alzheimer Dis Assoc Disord 20:224-31. 2006
    ..As a global cognitive measure, MMSE depends on the integrity of widely distributed cortical areas in both brain hemispheres with left-sided predominance...
  65. ncbi Neuropathologic correlates of apathy in Alzheimer's disease
    Gad A Marshall
    Department of Neurology, University of California at Los Angeles, Reed Neurological Research Center, 2 238, 710 Westwood Plaza, CA 90095 1769, USA
    Dement Geriatr Cogn Disord 21:144-7. 2006
    ..01, and r = 0.438, p = 0.032). This analysis suggests that chronic apathy in AD correlates with a greater anterior cingulate NFT burden and that chronic behavioral changes are more reflective than acute changes of disease pathology...
  66. ncbi Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia
    George Bartzokis
    Department of Neurology, The David Geffen School of Medicine at UCLA, USA
    Arch Gen Psychiatry 63:63-72. 2006
    ..This may result in a progressive "disconnection" of widely distributed neural networks that may underlie the age risk factor for AD...
  67. ncbi Deficits in facial emotion processing in mild cognitive impairment
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 23:271-9. 2007
    ..Patients with Alzheimer disease consistently demonstrate impaired performance on tests of facial emotion processing. However, it remains unclear how early in the neurodegenerative process these deficits emerge...
  68. ncbi Effective pharmacologic management of Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202 5111, USA
    Am J Med 120:388-97. 2007
    ....
  69. ncbi 3D mapping of language networks in clinical and pre-clinical Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Brain Lang 104:33-41. 2008
    ..Using a novel 3D mapping technique, we demonstrated that in AD language abilities are strongly influenced by the integrity of the perisylvian cortical regions...
  70. ncbi Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men
    Po H Lu
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
    Arch Neurol 63:177-85. 2006
    ..There is a compelling need for therapies that prevent, defer the onset, slow the progression, or improve the symptoms of Alzheimer disease (AD)...
  71. ncbi 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine UCLA, CA, USA
    Brain 129:2867-73. 2006
    ..Novel hippocampal analytic techniques that can track the spread of hippocampal pathology in 3D with such precision are a promising research tool...
  72. ncbi A potential role of the curry spice curcumin in Alzheimer's disease
    John M Ringman
    University of California, Los Angeles, Department of Neurology, Alzheimer s Disease Research Center, Los Angeles, CA 90095, USA
    Curr Alzheimer Res 2:131-6. 2005
    ..We are therefore performing a study of curcumin in patients with AD to gather this information in addition to data on the effect of curcumin on biomarkers of AD pathology...
  73. ncbi Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 24:253-9. 2007
    ..Depression and apathy may identify a subset of MCI subjects at higher risk of progression to Alzheimer's disease (AD). However, it remains uncertain whether a broader spectrum of psychopathology is associated with progression to AD...
  74. ncbi Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease
    George Bartzokis
    Department of Neurology, Univeristy of California School of Medicine, Los Angeles, CA 90095, USA
    Neurobiol Aging 25:843-51. 2004
    ..In AD this process is globally exacerbated, consistent with an extracellular deleterious process such as amyloid beta-peptide toxicity. Non-invasive measures such as R2 may be useful in primary prevention studies of AD...
  75. ncbi Microtenotomy using a radiofrequency probe to treat lateral epicondylitis
    James P Tasto
    San Diego Sports Medicine and Orthopedic Center, University of California, San Diego, La Jolla, California, USA
    Arthroscopy 21:851-60. 2005
    ..To evaluate the safety and effectiveness of microtenotomy using a radiofrequency (RF) probe to treat chronic tendinosis of the common extensor tendon origins of the elbow (lateral epicondyle)...
  76. ncbi Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect
    Erik P Pioro
    Section of ALS and Related Disorders, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Ann Neurol 68:693-702. 2010
    ..To evaluate dextromethorphan combined with ultra low-dose quinidine (DMq) for treating pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS)...
  77. ncbi Globalization of Alzheimer's disease clinical trials
    Jeffrey Cummings
    Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada 89106, USA
    Alzheimers Res Ther 3:24. 2011
    ..Attention to these potential influences on clinical trials will determine the success of global drug development programs and the utility of global trials for developing new AD therapeutics...
  78. ncbi A new measurement of activities of daily living for Thai elderly with dementia
    Vorapun Senanarong
    Division of Neurology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    Int Psychogeriatr 15:135-48. 2003
    ..It had high concurrent validity with previously published ADL scales. The methodology used to develop the Thai ADL scale can provide a model for creating culturally competent ADL scales...
  79. ncbi The neuropsychiatric burden of neurological diseases in the elderly
    Jeffrey L Cummings
    Int Psychogeriatr 17:341-51. 2005
  80. ncbi Prevalence and impact of medical comorbidity in Alzheimer's disease
    P Murali Doraiswamy
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Gerontol A Biol Sci Med Sci 57:M173-7. 2002
    ..We examined the prevalence of comorbid medical illnesses in Alzheimer's disease (AD) patients at different severity levels. We also examined the effect of cumulative medical comorbidity on cognition and function...
  81. ncbi Mild cognitive impairment
    Serge Gauthier
    McGill Center for Studies in Aging, Douglas Hospital, Montreal, Quebec, Canada
    Lancet 367:1262-70. 2006
    ..Other definitions and subtypes of mild cognitive impairment need to be studied as potential prodromes of Alzheimer's disease and other types of dementia...
  82. ncbi Neuropsychiatric symptoms and quality of life in Alzheimer disease
    Il-Seon Shin
    Department of Psychiatry, Chonnam National University Medical School, Kwangju, Republic of Korea
    Am J Geriatr Psychiatry 13:469-74. 2005
    ..CONCLUSION: Neuropsychiatric symptoms of AD patients adversely affect both patient and caregiver QOL. These results suggest that identifying and treating neuropsychiatric symptoms in AD may improve both patient and caregiver QOL...
  83. ncbi Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer's disease
    Vorapun Senanarong
    Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    Int Psychogeriatr 17:81-90. 2005
    ..291) and apathy (r = 0.342). CONCLUSIONS: We demonstrated correlations between ADL and behavioral changes in Thai elderly with AD. Our results emphasize the important relationships among behavioral changes and impaired ADL...
  84. ncbi Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences
    Murat Emre
    Department of Neurology, Istanbul Faculty of Medicine, Istanbul, Turkey
    J Alzheimers Dis 11:509-19. 2007
    ..In both populations, hallucinations may identify patients who are likely to be more treatment-responsive...
  85. ncbi The one-minute mental status examination
    Jeffrey L Cummings
    Neurology 62:534-5. 2004
  86. ncbi The impact of depressive symptoms on patients with Alzheimer disease
    Jeffrey L Cummings
    Alzheimer Dis Assoc Disord 17:61-2. 2003
  87. ncbi A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease
    George S Zubenko
    Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Room E1230, 3811 O Hara Street, Pittsburgh, PA 15213, USA
    Am J Psychiatry 160:857-66. 2003
    ....
  88. ncbi Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI)
    Sue J Kang
    Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong Kangnam-ku, Seoul 135-710, South Korea
    J Geriatr Psychiatry Neurol 17:32-5. 2004
    ..6, P<.001). Total CGA-NPI scores also correlated highly with total NPI scores (r= 0.86, P<.001). These results suggest that the CGA-NPI can substitute for the NPI, saving administration time...
  89. ncbi Executive dysfunction and apathy predict functional impairment in Alzheimer disease
    Patricia A Boyle
    Brown Medical School, Providence, RI, USA
    Am J Geriatr Psychiatry 11:214-21. 2003
    ..The purpose of this study was to examine the extent to which executive cognitive dysfunction and frontally-mediated behavioral disturbances are associated with functional impairment in patients with mild-to-moderate Alzheimer disease (AD)...
  90. ncbi Searching for methods to detect, prevent, and treat Alzheimer's disease
    Jeffrey L Cummings
    Am J Psychiatry 162:645-7. 2005
  91. ncbi Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association
    Donald R Royall
    The University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    J Neuropsychiatry Clin Neurosci 14:377-405. 2002
    ..The prevalence and severity of ECF deficits in many disorders remain to be determined, and treatment has been attempted in only a few disorders. Much more research in these areas is necessary...
  92. ncbi Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study
    Michael S Mega
    Alzheimers Disease Center and Center on Aging, Providence Health System, Portland, OR 97222
    Arch Neurol 62:721-8. 2005
    ..Regional brain correlates of treatment with cholinesterase inhibitors in those with Alzheimer disease are unknown...
  93. ncbi Measuring disease modification in Alzheimer's disease
    Jeffrey L Cummings
    CNS Spectr 12:11-4. 2007

Research Grants12

  1. IN VIVO CORRELATES OF NEUROPATHOLOGIC DIAGNOSIS IN ALZHEIMERS DISEASE
    Jeffrey Cummings; Fiscal Year: 2002
    ..2. To determine how Talairach coordinates predict anatomical lesion location. 3. To determine the spatial location of changes in the lesion over time. ..